ISSN: 1756-2856

Journal Home

Therapeutic Advances in Neurological Disorders Q1 Unclaimed

SAGE Publications Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Therapeutic Advances in Neurological Disorders is a journal indexed in SJR in Pharmacology and Neurology (clinical) with an H index of 75. It is an CC BY-NC Journal with a Single blind Peer Review review system, and It has a price of 1800 €. The scope of the journal is focused on neurological disorders, neurology. It has an SJR impact factor of 1,614 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,614.

Type: Journal

Type of Copyright: CC BY-NC

Languages: English

Open Access Policy: Open Access

Type of publications:

Publication frecuency: -

Categories: Neurology (Q1) Neurology (clinical) (Q1) Neurology (clinical) (Q1) Pharmacology (Q1)

Price

1800 €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Therapeutic Advances in Neurological Disorders

1,614

SJR Impact factor

75

H Index

101

Total Docs (Last Year)

274

Total Docs (3 years)

4379

Total Refs

1276

Total Cites (3 years)

258

Citable Docs (3 years)

3.97

Cites/Doc (2 years)

43.36

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Pharmacological Reviews Q1
Drug Resistance Updates Q1
Journal for ImmunoTherapy of Cancer Q1
Annual Review of Pharmacology and Toxicology Q1
Molecular Therapy Q1

Compare this journals

Aims and Scope

Neurological disorders Neurology

Best articles by citations

Noninvasive vagus nerve stimulation in the management of cluster headache: clinical evidence and practical experience

Magnetic resonance monitoring of lesion evolution in multiple sclerosis

Isoniazid in autoimmunity: a trigger for multiple sclerosis?

Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series

Natalizumab in pediatric multiple sclerosis patients

A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing - remitting multiple sclerosis (TIME MS)

Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis

Natalizumab: increased vigilance is required in treating patients with multiple sclerosis

Health-related quality of life as an outcome variable in Parkinson's disease

Percutaneous transluminal angioplasty and stenting for symptomatic intracranial arterial stenosis: a systematic review and meta-analysis

Correlation of hyperglycemia with mortality after acute ischemic stroke

Therapeutic strategies in childhood multiple sclerosis

SHOW MORE ARTICLES

Sumatriptan/naproxen sodium combination versus its components administered concomitantly for the acute treatment of migraine: a pragmatic, crossover, open-label outcomes study

A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple scleros

Neuroimaging of motor neuron diseases

Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage

Neuroradiological evaluation of demyelinating disease

Review: Future perspectives for brain pharmacotherapies: implications of drug transport processes at the blood - brain barrier

From injection therapies to natalizumab: views on the treatment of multiple sclerosis

The role of pramipexole in a severe Parkinson's disease model in mice

Progress in enzyme replacement therapy in glycogen storage disease type II

The physiological basis of therapies for cerebellar ataxias

Current and future treatment approaches for neuromyelitis optica

The prospects of CRISPR-based genome engineering in the treatment of neurodegenerative disorders